

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

ES6

RRID:CVCL_1202

Type: Cell Line

Proper Citation

RRID:CVCL_1202

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1202

Proper Citation: RRID:CVCL_1202

Description: Cell line ES6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Ewing sarcoma

Defining Citation: [PMID:20164919](#), [PMID:25010205](#), [PMID:26351324](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ES6

Synonyms: ES-6

Cross References: CLO:CLO_0009863, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, cancercellines:CVCL_1202, Cell_Model_Passport:SIDM00262, ChEMBL-Cells:ChEMBL3308152, ChEMBL-Targets:ChEMBL2366373, Cosmic:684058, Cosmic:949157, Cosmic:2228225, Cosmic-CLP:949157, DepMap:ACH-002107, EGA:EGAS00001000978, GDSC:949157, GEO:GSM1669773, GEO:GSM1676357, GEO:GSM1701687, IARC_TP53:27158, LINCS_LDP:LCL-1443, PharmacDB:ES6_342_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_1202, Wikidata:Q54832643

ID: CVCL_1202

Record Creation Time: 20220427T215837+0000

Record Last Update: 20260913T003047+0000

Ratings and Alerts

No rating or validation information has been found for ES6.

No alerts have been found for ES6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Koppenhafer SL, et al. (2026) DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. *Oncogene*, 45(28), 2823.

Koppenhafer SL, et al. (2025) Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. *Cancer research communications*, 5(6), 1034.

Del Pozo V, et al. (2022) PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma. *iScience*, 25(2), 103725.

Charan M, et al. (2020) GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. *International journal of cancer*, 146(11), 3184.